MONTREAL, May 26, 2022
/CNW Telbec/ - Lumiera Health
Inc. (TSXV: NHP) (the "Company" or
"Lumiera "), a company specializing in the development
and commercialization of natural health products, is pleased to
announce the retail expansion of its Awaye™ pain relief cream.
Awaye™ is now available at Rachelle Béry health food
stores. Rachelle Béry, is a natural health food chain part of
Sobeys Inc.'s retail network.
Rachelle Béry opened its first natural products grocery store
over 35 years ago. Today, with 11 grocery stores and over 70
In-store locations in IGA supermarkets throughout Québec, the
banner has become a leader in organic and natural products across
the province.
"The Rachelle Béry brand is recognized as a trusted retailer of
natural products by Québec consumers. Having Awaye™ on the
shelves at Rachelle Béry represents not only a badge of quality but
also a significant milestone for our product in terms of retail
distribution," says Carlos Ponce,
CEO of Lumiera." As per our previous announcements, we are
pleased with Awaye™'s e-commerce progress and we are now focused on
building retail distribution so that everyone has access to the
natural pain relief that Awaye™ provides, regardless of where
people shop. We are excited to working with our current and future
retail partners to continue expanding distribution and consumer
trial. This is another positive step on Awaye™'s accelerated growth
plans and we look forward to sharing more details are we further
expand distribution and availability."
About Awaye™
Awaye™ provides a new generation of relief from acute and
chronic pain by exploiting the CB2 receptors of the endocannabinoid
system, the body's built-in pain and inflammation defense system.
Awaye™ is a unique Health Canada approved topical cream that
provides relief from pain through complimentary mechanisms of
action not found in any other product currently available on the
market.
For more information about Awaye™ products, visit
www.awaye.ca
About Lumiera
Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also commercializing a unique
topical product line acting on the endocannabinoid system, without
the use of cannabis, that provides an innovative solution for
chronic pain and inflammation. A pioneer in the natural health
innovation space, the Lumiera brand is rooted in the core values of
science, nature and compassion. Our goal is to make people's
lives better by developing natural health and wellness products
that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking
information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2021,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Lumiera Health Inc.